Benefits
Accelerated innate antiviral immune response
Low-dose cRG-I has been associated with faster interferon-induced antiviral responses to rhinovirus infection in humans, supporting an immune-priming effect of dietary RG-I beyond classical prebiotic fermentation. This rests on one manufacturer-funded trial in 177 people who were deliberately inoculated with rhinovirus-16 in a laboratory. The dose pattern was inconsistent: innate immune activation was strongest at 1.5 g/day, while the faster interferon response and faster viral clearance came at 0.3 g/day.
Symptom severity and duration after a laboratory rhinovirus challenge
Low-dose cRG-I was associated with reduced symptom severity and shorter symptom duration versus placebo in healthy adults. Severity was about 20 percent lower and duration about 25 percent shorter at 0.3 g/day, in a single trial of 177 people. The infection was a deliberate laboratory inoculation with rhinovirus-16 in healthy 18 to 65 year olds; nothing here tested colds caught naturally over a winter. The 1.5 g/day dose did less well than 0.3 g/day.
More Bifidobacterium, overall microbiota largely unchanged
Daily supplementation with rhamnogalacturonan-I left the overall gut microbiota composition generally unaltered in the one trial that measured it, which the authors put down to the very low fiber dose. What did change: relative abundance of Bifidobacterium, mainly B. adolescentis and B. longum, rose significantly at both 0.3 and 1.5 g/day, and microbiota variability between and within people fell in a dose-dependent way. The same paper reports that respiratory symptom severity did not directly correlate with these microbial changes.
Studied at low daily doses
Unlike traditional fiber-style prebiotics that often require multi-gram doses, cRG-I appears clinically active at sub-gram intakes (~0.3 g/day). In practice that means a small capsule rather than a fiber scoop. It also means more is not better here: the 1.5 g/day arm did less well than 0.3 g/day on symptoms and viral clearance, and the reason is unknown.
Mechanism of action
Direct gut immune signalling via pattern recognition
RG-I pectic polysaccharides are thought to interact with pattern-recognition receptors on intestinal epithelial cells and resident immune cells, modulating cytokine and interferon signalling. The evidence for this receptor interaction comes from laboratory and animal work; it was not measured in the human trial, so treat it as a proposed explanation rather than a demonstrated one.
Innate antiviral priming of interferon pathways
Daily cRG-I supplementation is associated with faster type I interferon responses after deliberate rhinovirus-16 inoculation in one human trial. Priming of the innate antiviral interferon pathway is the leading hypothesis for the observed reductions in cold-type symptom severity and duration.
Microbiota composition modulation
The microbiota substudy found the overall community composition generally unaltered at these low doses. One change was clear: more Bifidobacterium at both 0.3 and 1.5 g/day, alongside a dose-dependent drop in how much microbiota profiles varied between and within people. Whether any of that drives the respiratory result is unknown, since symptom severity did not track the microbial changes.
Clinical trials
Randomized, placebo-controlled trial of carrot-derived rhamnogalacturonan-I (cRG-I) at 0, 0.3, or 1.5 g/day in 177 healthy individuals aged 18–65 years before and during experimental rhinovirus-16 challenge. Primary outcomes were symptom severity, symptom duration and viral load in nasal lavage; innate immune and interferon markers were secondary. Published in Nutrients, Lutter 2021. Funded by NutriLeads, which supplied the product and had a role in study design, data analysis, data interpretation and writing the report.
177 healthy adults aged 18 to 65. After eight weeks of supplementation they were deliberately inoculated with rhinovirus-16 in a laboratory; nobody caught a cold naturally.
At 0.3 g/day cRG-I, participants experienced a faster interferon-induced response and reduced symptom severity (~20%) and duration (~25%) versus placebo. The higher 1.5 g/day dose produced the strongest innate immune activation, yet its antiviral response, viral clearance and symptom scores fell between placebo and 0.3 g/day. A higher dose working less well is unexplained and is a reason for caution rather than confidence. All three trial entries on this page come from this single study.
Secondary analysis of the same rhinovirus-16 challenge trial, not a new study. Its stated aim was to elaborate on the initial findings. It adds ex vivo whole-blood TLR3 stimulation, NK cell function and quality-of-life scores in the same participants. Published in Nutrients, McKay 2022. Funded by NutriLeads.
The same volunteers as the 2021 trial. No new participants were enrolled.
cRG-I supplementation was associated with accelerated immune responses and improvements in quality-of-life measures during rhinovirus challenge. Because this analyses the same participants rather than a second study, it cannot independently confirm the first result. Count the three papers on this page as one trial.
Gut microbiota substudy of the same rhinovirus-16 challenge trial, not a separate study. Participants took placebo (n=46), 0.3 g/day (n=49) or 1.5 g/day (n=51) for eight weeks before the challenge. Published in Biomedicine & Pharmacotherapy, Jian 2024. Funded by NutriLeads.
The same trial cohort; the microbiota substudy reports 46 people on placebo, 49 at 0.3 g/day and 51 at 1.5 g/day, 146 in all.
Daily supplementation with rhamnogalacturonan-I left the overall gut microbiota composition generally unaltered, which the authors put down to the very low fiber dose. Bifidobacterium relative abundance, mainly B. adolescentis and B. longum, increased significantly at both doses, and microbiota heterogeneity between and within people fell in a dose-dependent way. The authors also state that the severity of respiratory symptoms did not directly correlate with the cRG-I-induced microbial changes.